We seek to develop a potent and selective negative allosteric modulator of “Dual-specificity tyrosine-(Y)-phosphorylation Regulated Kinase-1A” (DYRK1A) to treat neuroinflammatory and neurodegenerative diseases such as Parkinson’s disease (PD). The gene discussed is DYRK1A; the disease is Parkinson disease.